Summarized by Masters of Longevity from Nature - Main.
Prime editing in humans — a news feature previewing a clinical first that tests direct in-body DNA rewriting as a potential one‑time treatment.
Key Takeaways
- Prime editing was administered in vivo to a patient with Wilson disease to target ATP7B liver mutations.
- Prime Medicine treated the first participant and plans to report initial trial results next year.
- No gene-editing therapy has yet been approved for in vivo use, though FDA decisions on related therapies are pending.
